Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bilcare names new general manager for EU operations
Prior to joining Bilcare Global Clinical Supplies (GCS), Mr Moult worked as senior director of clinical trial supplies for UCB (Belgium) where he was also integral to technical
Prior to joining Bilcare Global Clinical Supplies (GCS), Mr Moult worked as senior director of clinical trial supplies for UCB (Belgium) where he was also integral to technical
“Our 2008 accomplishments were marked by substantial progress across our product pipeline, in particular by successfully demonstrating the therapeutic potential of SGN-35 and the promise of our antibody-drug
Haemonetics asserted that Fenwal’s blood collecting device infringed its patent for an automated blood collection system. The case was heard in the U.S. District Court for Massachusetts (No.
The technology provides a platform of diagnostic tests used by physicians and researchers to monitor the success of anti-HIV treatment by determining drug resistance and disease strength of
The company has said that it has begun accepting orders for the solution and has started commercial production of the solution’s components for shipment during the first quarter
Net income of $2.0 million for the fourth quarter of 2008 and $3.1 million of net income for 2008 Consolidated fourth quarter revenue of $28.2 million, up 31
The Realism study is a prospective, multi-center, continued access registry of the Everest II study. The Realism study consists of two arms: a high risk arm and a
In a study conducted by Barry Eppley, 23 female patients (ages 19 to 37) with problematic menstrual issues used the Allay patch continuously for five days when the
Arlington Neonatal Intensive Care is a two-physician practice that staffs the Level III neonatal intensive care unit (NICU) at Texas Health Arlington Memorial Hospital, which has annual patient
In addition, Terrance Gregg, DexCom’s president and CEO, also purchased 150,000 additional shares of common stock in this offering at a per share price of $3.12, which represents